Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer
Our findings suggest that a Next-Generation Sequencing (NGS) multigene panel is useful in predicting BCG response in patients with NMIBC.
Authors
- Giuseppe Giannini (ORCID: https://orcid.org/0000-0003-0299-4056)
- Ettore De Berardinis (ORCID: https://orcid.org/0000-0003-1498-2810)
- Michela De Meo (ORCID: https://orcid.org/0000-0002-3024-2233)
- Valentina Magri (ORCID: https://orcid.org/0000-0001-7312-2904)
- Luca Marino (ORCID: https://orcid.org/0000-0001-7380-6222)
- B.I. Chung
- Chiara Nicolazzo (ORCID: https://orcid.org/0000-0002-2551-8979)
- P. Gazzaniga
- Carlo Maria Scornajenghi (ORCID: https://orcid.org/0000-0001-7600-7434)
- Francesco Del Giudice (ORCID: https://orcid.org/0000-0003-3865-5988)
- Jan Łaszkiewicz (ORCID: https://orcid.org/0009-0008-2306-0854)
- Fabio Massimo Magliocca
- Francesca Bettarini
Institutions
- Medical University of Silesia (PL)
- University Medical Center (US)
- Istituto Pasteur (IT)
- Sapienza University of Rome (IT)
- Stanford University (US)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2024-11-05
- DOI
- https://doi.org/10.32604/or.2024.056282
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Sapienza Università di Roma